Trial Profile
Comparative Effectiveness and Safety Between Warfarin and Dabigatran Using Real World Claims Data of Japanese Non-valvular Atrial Fibrillation Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Jul 2019
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Warfarin (Primary)
- Indications Embolism and thrombosis; Stroke
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 20 Apr 2018 Status changed from not yet recruiting to completed.
- 18 Oct 2017 Planned End Date changed from 25 Oct 2017 to 19 Dec 2017.
- 18 Oct 2017 Planned primary completion date changed from 12 Oct 2017 to 6 Dec 2017.